Why the study?
Does celecoxib prevent gastrointestinal complications compared to diclofenac plus omeprazole in patients who had previously had bleeding?
Does celecoxib prevent gastrointestinal complications compared to diclofenac plus omeprazole in patients who had previously had bleeding?
This editorial discusses the comparative gastrointestinal safety of COX-2 inhibitors versus traditional NSAIDs plus proton pump inhibitors in high-risk patients.
Widespread use of nonsteroidal antiinflammatory drugs (NSAIDs) among the elderly has resulted in a large population of persons at risk for ulcer complications. Selective cyclooxygenase-2 (COX-2) inhibitors were introduced with the hope that they would not cause gastrointestinal complications. However, it is not clear that this has been the case, and now that the dust has settled somewhat, it is possible to take a dispassionate look at the problem.1,2 In this issue of the Journal, Chan et al.3 report a randomized comparison of celecoxib and diclofenac plus omeprazole among patients in Hong Kong who had previously had bleeding from . . .
No takes yet. Share an insight, caveat, or question.
David Y. Graham (2002) conducted an editorial in Ulcer complications. Celecoxib vs. Diclofenac plus omeprazole was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: